6β-Brom-5α-cholestan-3β,5-diol | 1857-83-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6β-Brom-5α-cholestan-3β,5-diol
• 英文别名: 6β-bromo-5α-cholestane-3β,5-diol；(3S,5R,6R,8S,9S,10R,13R,14S,17R)-6-bromo-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5-diol
• CAS: 1857-83-6
• 化学式: C₂₇H₄₇BrO₂
• 分子量: 483.573
• InChiKey: CKIVNXXOUPHIAY-RUXQDQFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6β-Brom-5α-cholestan-3β,5-diol 在 chromium(VI) oxide 作用下， 以 溶剂黄146 、 苯 为溶剂， 生成 6β-bromo-5-hydroxy-5α-cholestan-3-one
  参考文献：
  名称：

  Jacquesy,J.-C.; Levisalles,J., Bulletin de la Societe Chimique de France, 1965, p. 1538 - 1544

  摘要：

  DOI：
• 作为产物：
  描述：

  胆固醇-5Alpha,6Alpha-环氧化物 在 氢溴酸 作用下， 以 氯仿 为溶剂， 生成 6β-Brom-5α-cholestan-3β,5-diol
  参考文献：
  名称：

  Jacquesy,J.-C.; Levisalles,J., Bulletin de la Societe Chimique de France, 1965, p. 1538 - 1544

  摘要：

  DOI：

文献信息

• [EN] HALOGENATED CHOLESTEROL ANALOGUES AND METHODS OF MAKING AND USING SAME<br/>[FR] ANALOGUES HALOGÉNÉS DU CHOLESTÉROL ET LEURS PROCÉDÉS DE PRÉPARATION ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2020069267A1

  公开（公告）日：2020-04-02

  Provided herein are halogenated cholesterol analogues, including methods of making and using the same. Also provided are methods of making radiolabeled cholesterol analogues including admixing an epoxide with a fluorine-18 source under conditions to form a radiofluorinated cholesterol analogue.

  本文提供了卤代胆固醇类似物，包括其制备和使用方法。还提供了制备放射标记胆固醇类似物的方法，包括在条件下将环氧化合物与氟-18源混合以形成放射氟标记的胆固醇类似物。
• Mori; Mukawa, Proceedings of the Imperial Academy (Tokyo), 1955, vol. 31, p. 532,534
  作者：Mori、Mukawa

  DOI：——

  日期：——
• Viruses associated with outbreaks of equine respiratory disease in New Zealand
  作者：M Dunowska、CR Wilks、MJ Studdert、J Meers

  DOI：10.1080/00480169.2002.36299

  日期：2002.8

  AIM: To identify viruses associated with respiratory disease in young horses in New Zealand.METHODS: Nasal swabs and blood samples were collected from 45 foals or horses from five separate outbreaks of respiratory disease that occurred in New Zealand in 1996, and from 37 yearlings at the time of the annual yearling sales in January that same year. Virus isolation from nasal swabs and peripheral blood leukocytes (PBL) was undertaken and serum samples were tested for antibodies against equine herpesviruses (EHV-1, EHV-2, EHV-4 and EHV-5), equine rhinitis-A virus (ERAV), equine rhinitis-B virus (ERBV), equine adenovirus 1 (EAdV-1), equine arteritis virus (EAV), reovirus 3 and parainfluenza virus type 3 (PIV3).RESULTS: Viruses were isolated from 24/94 (26%) nasal swab samples and from 77/80 (96%) PBL samples collected from both healthy horses and horses showing clinical signs of respiratory disease. All isolates were identified as EHV-2, EHV-4, EHV-5 or untyped EHV Of the horses and foals tested, 59/82 (72%) were positive for EHV-1 and/or EHV-4 serum neutralising (SN) antibody on at least one sampling occasion, 52/82 (63%) for EHV-1-specific antibody tested by enzyme-linked immunosorbent assay (ELISA), 10/80 (13%) for ERAV SN antibody, 60/80 (75%) for ERBV SN antibody, and 42/80 (53%) for haemagglutination inhibition (HI) antibody to EAdV-1. None of the 64 serum samples tested were positive for antibodies to EAV, reovirus 3 or PIV3. Evidence of infection with all viruses tested was detected in both healthy horses and in horses showing clinical signs of respiratory disease. Recent EHV 2 infection was associated with the development of signs of respiratory disease among yearlings [relative risk (RR) = 2.67, 95% CI = 1.59-4.47, p = 0.0171].CONCLUSIONS: Of the equine respiratory viruses detected in horses in New Zealand during this study, EHV 2 was most likely to be associated with respiratory disease. However, factors other than viral infection are probably important in the development of clinical signs of disease.